Dr. Kumar’s Take:
This is a single 3-year randomized, placebo-controlled trial in 244 healthy postmenopausal women, not a meta-analysis, and I read it as good evidence that daily low-dose Vitamin K2 (MK-7) helps slow bone loss after menopause. The supplement improved vitamin K status, reduced the age-related decline in bone mineral density at the lumbar spine and femoral neck, and favorably affected bone strength compared with placebo. This is a slow-acting intervention measured over years, so consistency matters.
If you’re postmenopausal and looking for non-drug ways to support bone health, this is a reasonable case for adding MK-7 to your routine.
Key Takeaways:
✔ 180 µg of MK-7 daily improved bone health measures over 3 years
✔ Spine and femoral neck bone density loss was slowed in the MK-7 group
✔ Markers of vitamin K status improved, reflecting better osteocalcin carboxylation
✔ Total hip bone mineral density was not affected
Actionable Tip:
Consider adding 180 µg of MK-7 (menaquinone-7) daily if you are postmenopausal and concerned about bone loss. Choose a supplement with verified stability and quality.
Brief Summary:
This 3-year trial randomized 244 healthy postmenopausal women to either placebo or 180 µg/day of MK-7. Bone mineral content and bone mineral density in the lumbar spine and femoral neck declined more slowly in the MK-7 group, and bone strength indices of the femoral neck were favorably affected. Vitamin K status improved, measured as the ratio of uncarboxylated osteocalcin to carboxylated osteocalcin. Total hip bone mineral density did not differ.
Study Design:
- Type: 3-year randomized, placebo-controlled trial
- Participants: 244 healthy postmenopausal women
- Groups: Placebo vs. 180 µg/day MK-7
- Measurements: Bone mineral density of the lumbar spine, total hip, and femoral neck by DXA; femoral neck bone strength indices; vertebral fracture assessment by DXA; circulating uncarboxylated and carboxylated osteocalcin
- Timing: Measurements at baseline and after 1, 2, and 3 years
Results:
Vitamin K status improved:
- The ratio of uncarboxylated to carboxylated osteocalcin improved with MK-7
Bone mineral density:
- Slower age-related decline in lumbar spine and femoral neck bone mineral content and bone mineral density
- No effect at the total hip
Bone strength indices (femoral neck):
- Favorably affected by MK-7
Vertebral height:
- Loss of vertebral height at the mid-site of the lower thoracic vertebrae was significantly lower in the MK-7 group
How Vitamin K2 (MK-7) Supports Bone Health
Vitamin K2 activates proteins involved in bone through carboxylation, which allows proteins like osteocalcin to bind calcium. MK-7 is a long-chain menaquinone with a longer half-life and greater potency than the short-chain menaquinone-4, which is why this trial used a low dose and still improved vitamin K status. Earlier work by the same group found that 3 years of high-dose vitamin K1 (phylloquinone) and short-chain MK-4 also improved bone health after menopause, and the European Food Safety Authority has accepted a health claim for vitamin K’s role in maintaining normal bone.
Related Studies and Research
- Is Vitamin K2 a Blood Thinner? No, It Does the Opposite Three-year RCT evaluating low-dose MK-7’s impact on bone loss in healthy postmenopausal women.: Core trial assessing MK-7’s capacity to preserve bone mass.
Comprehensive meta-analysis of randomized trials on MK-7 supplementation and osteoporosis prevention in postmenopausal women.: Meta-level evidence of K2’s bone benefits.
Analysis of warfarin therapy’s relationship with increased osteoporotic fracture risk in elderly atrial fibrillation patients.: Evaluates fracture risk under anticoagulation.
Examines warfarin’s influence on bone mineral density reduction and fracture incidence.: Detailed look at BMD declines with warfarin.
Population-based study linking habitual natto consumption to higher bone density in elderly Japanese women.: Observational link between natto and bone density.
Frequently Asked Questions
Is MK-7 a better supplement than MK-4?
MK-7 is a long-chain menaquinone with a longer half-life and greater potency than short-chain MK-4, which is why this trial was able to use a low daily dose and still improve vitamin K status.
How long do I need to take MK-7 to see benefits?
This trial ran for 3 years, with measurements at baseline and at 1, 2, and 3 years. MK-7 is a long game supplement.
Do these results apply to me if I am not a postmenopausal woman?
The trial enrolled only healthy postmenopausal women. The authors state that whether these results extend to other groups, such as children and men, needs further investigation.
Can MK-7 be taken with calcium or vitamin D?
This trial tested MK-7 against placebo, so it does not answer that question directly. Combining them is common in practice.
Conclusion
Three years of MK-7 at 180 µg/day slowed the age-related decline in bone mineral density and bone strength in healthy postmenopausal women, and improved vitamin K status. On the strength of this trial, MK-7 is a reasonable daily addition to a bone health regimen after menopause.
